References and study parameters

  1. Victoza® Product Monograph, Novo Nordisk Canada Inc., April 19, 2016.

  2. Data on file [IMS], Novo Nordisk Canada Inc., June 2016.

  3. Data on file [IMS], Novo Nordisk Canada Inc., September 2015.

  4. Davies MJ et al. Efficacy and Safety of Liraglutide vs Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care. 2016;39(2):222-230.

    A 26-week, double-blind, placebo-controlled, parallel-group trial randomized 279 patients with type 2 diabetes and moderate renal impairment (eGFR 30–59 mL/min/1.73 m2) to once-daily Victoza® 1.8 mg (n=140) or placebo (n=139) as add-on to insulin ± OADs. The primary outcome measure was change in A1C from baseline to week 26. Baseline values for Victoza® 1.8 mg (n=140) and placebo (n=137): A1C (%): 8.08 and 8.00, respectively; body weight (kg): 93.6 and 95.6, respectively.

  5. Bailey TS et al. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH™): a randomized, double-blind, double-dummy, active-controlled 26-week trial. Diabetes Obes Metab. 2016. doi: 10.1111/dom.12736.

    A 26-week, multicentre, parallel-group, double-blind, double-dummy, active-controlled trial randomized 406 patients with type 2 diabetes, HbA1c 7.5–9.5%, body mass index (BMI) ≥20 kg/m2, previously treated with stable doses of sitagliptin (100 mg/day) and metformin ( ≥1500 mg/day or maximum tolerated dose ≥1000 mg/day) for ≥90 days to once-daily Victoza® 1.8 mg + sitagliptin placebo (n=202) or sitagliptin 100mg/day + Victoza® placebo (n=204) as add-on to metformin. The primary endpoint was change in HbA1c from baseline to week 26. A confirmatory secondary endpoint was change in body weight from baseline to week 26. Other secondary endpoints included: subjects meeting HbA1c target <7.0% (ADA target); composite endpoint of subjects achieving HbA1c <7.0% and no weight gain. Baseline values for Victoza® 1.8 mg + sitagliptin placebo (n=202) and sitagliptin 100mg/day + Victoza® placebo (n=204): A1C (%): 8.3 and 8.2, respectively; body weight (kg): 88.9 and 91.2, respectively.

  6. Quick Reference Guide: 2013 Clinical Practice Guidelines (updated Nov 2016). Canadian Diabetes Association. November 2016.

Ask Med Info

If you have a specific question about Victoza®, please email our Medical Information team using the form below. We will get back to you as soon as possible.



Resources

The latest Victoza® Product Monograph dated June 15, 20171.

The new Victoza® VIP program is a resource for you to use with your patients during consultations, including how-to videos and other resources to get them started.

TRUST in our real-world experience.

#1 GLP-1 receptor agonist dispensed, Canada and worldwide2,3

>1,130,000 patients worldwide have been prescribed Victoza® 3